Gynecologic cancer is cancer originating in the female reproductive organs. It includes cancers of the uterus, ovaries, cervix, fallopian tubes, vulva and vagina, and accounts for over 80,000 new cancers diagnosed in the US every year. Approximately half of these cases are uterine cancer. The risk of getting cancer increases with age, though inherited cancers due to gene mutations or a family history of cancer may increase the risk. Knowledge is Power: Visit Clinical Cancer Genetics to learn more.
At Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, our treatment team is dedicated to providing the best care for women with or at ris for gynecologic cancer, both in the areas of treatment and research. With research and treatment areas under one roof, our physicians and researchers are better able to facilitate the translation of research advances to patient care. Recent research advancements include:
- Being among the first nationwide to be certified to perform minimally invasive robotic surgery on women with gynecologic cancer. Our faculty routinely use the latest robotic technologies to perform hysterectomies and lymph node dissections for treating uterine, cervical and ovarian cancers. The James was one of the first institutions in the country to use robotic technology to treat gynecologic cancers, and is currently one of the most active robotic groups in the country. Robotics has been used in heart and prostate surgeries for years, but now the federal Food and Drug Administration has cleared this minimally invasive technique for treatment of certain gynecological disorders.
- A new NCI-supported clinical trial conducted at the OSUCCC – James and other centers indicates that women with advanced ovarian cancer can benefit from treatment with two chemotherapy drugs, each delivered in a different way, following surgery. The treatment delivers one drug into a vein (IV) and the other drug directly into the abdomen (or intraperitoneal, IP therapy). The treatment extends the survival of women with advanced ovarian cancer compared to women receiving all of their treatment IV.
- A study by physicians at the OSUCCC – James and other institutions affiliated with the Gynecology Oncology Group to change the way that recurrent ovarian cancer is treated. The use of a naturally occurring virus (reovirus, known as Reolysin) in combination with a standard chemotherapy (paclitaxel) is being tested against paclitaxel alone. David E. Cohn, MD, is overseeing the study at The James and across the country.
- Investigation into novel strategies to target ovarian cancer blood vessel growth (angiogenesis) continue, and includes the use of an antibody (bevacizumab) in combination with standard chemotherapy (in clinical trials being conducted by David M. O’Malley, MD and Ritu Salani, MD, MBA). In addition, novel vaccine strategies against angiogenesis have been designed and is currently being tested for its ability to decrease ovarian cancer growth in the laboratory.
- A five-year, $7.5 million grant from the National Cancer Institute to OSUCCC investigators to address cancer issues among under served populations. It has been used to form a Center for Population Health and Health Disparities initially focusing on understanding why high rates of cervical cancer incidence and mortality are observed in Appalachian Ohio, a predominantly rural area in the southern and eastern parts of the state. David E. Cohn, MD, is the co-investigator from the Division of GYN Oncology for this study at The James.
- A study suggesting that women with endometrial (uterine ) cancer should be screened for mutations for Lynch syndrome, an inherited condition that carries a high risk for colon, uterine, ovarian and gastric cancers.
This section of the Web site will give you access to:
If you have questions about gynecologic cancer, please call The James Line – a free cancer information resource and physician referral service – at 614-293-5066 or 1-800-293-5066 (outside Franklin County) or e-mail now. The James Line oncology nurses can be reached Monday-Friday 8:00 a.m.-5:00 p.m. (except weekends and holidays).